Biotech ETF On The Brink Of A Breakout
Written by David Fabian, February 16th, 2017
The volatility in the biotech space over the last two years has been quite a sight to behold. I’m not strictly speaking of volatility in terms of downside either. There has been money to be made on both sides of the market for those that have been nimble in their trades.
Most ETF investors are probably familiar with trading the iShares NASDAQ Biotechnology ETF (IBB). This market-cap weighted giant has $8.2 billion dedicated to a basket of 164 stocks in the biotech research and medical services fields. As you can see on the chart below, this index has been on a rollercoaster ride of whipsaws in both directions over the last year.